

Title: Acute pulmonary embolism in patients presenting pulmonary deterioration after hospitalization for non-critical COVID-19.

Short running head: Pulmonary embolism in non-critical COVID-19 patients

Authors: Hernan Polo Friz^a, Elia Gelfi^a, Annalisa Orenti^b, Elena Motto^a, Laura Primitz^a, Tino Donzelli^a, Marcello Intotero^c, Paolo Scarpazza^d, Giuseppe Vighi^a, Claudio Cimminiello^e, Patrizia Boracchi^b.

Institutions:

^a Internal Medicine, Medical Department, Vimercate Hospital, ASST di Vimercate, Vimercate, Italy.

^b Department of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Epidemiology and Biometry G. A. Maccacaro, University of Milan, Milan, Italy.

^c Radiology, Diagnostic Department, Vimercate Hospital, ASST Vimercate, Vimercate, Italy.

^d Pulmonology, Medical Department, Vimercate Hospital, ASST Vimercate, Vimercate, Italy.

^e Research and Study Center of the Italian Society of Angiology and Vascular Pathology (Società Italiana di Angiologia e Patologia Vascolare, SIAPAV), Milan, Italy.

Corresponding Author:

Hernan Polo Friz. M.D.

Department of Medicine, Vimercate Hospital, Azienda Socio Sanitaria Territoriale (ASST) di Vimercate, via Santi Cosma e Damiano 10. ZIP 20871. Vimercate (MB) Italy. Phone number +39 039 6657504

e-mail: hernanemilio.plofriz@asst-vimercate.it, polofriz@libero.it

Conflict of interest/funding disclosure/authorship/CRedit

Conflict of Interest: None to declare. **Writing assistance:** None to declare. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The work has not been published previously and it is not under consideration for publication elsewhere. **Authorship:** authors declare that all have made substantial contributions to the conceptualization and design of the work, the acquisition, analysis, and the interpretation of data. HPF and EG performed the initial drafting of the work. All authors revised critically the draft adding important intellectual content. **All authors approve the final version to be published.**

CRedit author statement:

HPF: Conceptualization – Methodology - Formal analysis – Investigation - Data curation- Writing Review and Editing – Supervision - Project administration

EF: Methodology - Investigation - Data curation- Writing Review and Editing

AO: Methodology - Formal analysis –Data curation- Writing Review and Editing

EM: Investigation - Data curation- Writing Review and Editing

TD: Conceptualization –Investigation - Data curation- Writing Review and Editing

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the [Version of Record](#). Please cite this article as doi: [10.1111/imj.15307](https://doi.org/10.1111/imj.15307)

MI: Conceptualization –Investigation - Writing Review and Editing
PS: Conceptualization –Investigation - Writing Review and Editing
GV: Conceptualization – Methodology - Writing Review and Editing – Supervision
CC: Conceptualization – Methodology - Writing Review and Editing – Supervision
PB: Conceptualization – Methodology - Formal analysis –Data curation- Writing Review and Editing – Supervision

WORD COUNT:

Abstract: 246

Main text: 2907

References: 908

ABSTRACT

BACKGROUND. Emerging evidence suggests an association between COVID-19 and acute pulmonary embolism (APE).

AIMS. To assess the prevalence of APE in patients hospitalized for non-critical COVID-19 who presented clinical deterioration, and to investigate the association of clinical and biochemical variables with a confirmed diagnosis of APE in these subjects.

METHODS. All consecutive patients admitted to the internal medicine department of a general hospital with a diagnosis of non-critical COVID-19, who performed a Computer Tomography Pulmonary Angiography (CTPA) for respiratory deterioration in April 2020, were included in this retrospective cohort study.

RESULTS. Study populations: 41 subjects, median(IQR)age:71.7(63-76)years, CTPA confirmed APE=8(19.51%,CI95%:8.82%-34.87%). Among patients with and without APE, no significant differences were found with regards symptoms, comorbidities, treatment, Wells score and outcomes. The optimal cut-off value of D-dimer for predicting APE was 2454 ng/mL, sensitivity(CI95%):63(24-91), specificity:73(54-87), Positive Predictive Value:36(13-65), Negative Predictive Value: 89(71-98) and AUC:0.62(0.38-0.85). The standard and age-adjusted D-dimer cut-offs, and the Wells score ≥ 2 did not associate with confirmed APE, albeit a cut-off value of D-dimer=2454 ng/mL showed an RR:3.21;CI95%:0.92-13.97;p=0.073. Heparin at anticoagulant doses was used in 70.73% of patients before performing CTPA.

CONCLUSION. Among patients presenting pulmonary deterioration after hospitalization for non-critical COVID-19, the prevalence of APE is high. Traditional diagnostic tools to identify high APE pre-test probability patients do not seem to be clinically useful. These results support the use of a high index of suspicion for performing CTPA to exclude or confirm APE as the most appropriate diagnostic approach in this clinical setting.

Key Words: COVID-19, venous thromboembolism, pulmonary embolism, D-dimer, CT Angiography.

INTRODUCTION

Coronavirus disease (COVID-19) is an illness caused by severe acute respiratory syndrome coronavirus – 2 (SARS-CoV-2). The first cases of COVID-19 were reported in the city of Wuhan, China, in December 2019, and in the following weeks the infection spread across China and in other countries [1-2].

The clinical presentation of COVID-19 can be very varied, and encompasses asymptomatic infection, mild illness affecting the upper respiratory tract, and severe pneumonia, which may cause life-threatening respiratory failure [3]. The severity of COVID-19 cases has been classified as mild, moderate, severe, and critical [4].

Emerging evidence suggests that COVID-19 can be complicated by acute pulmonary embolism (APE) [5-7], and D-dimer values have been linked to a higher risk of death in patients with COVID-19 [8].

Although data from different studies indicate that the incidence of venous thromboembolism (VTE) in COVID-19 patients is higher than figures seen in similarly ill hospitalized non COVID-19 subjects, the exact prevalence of APE in COVID-19 patients is not known, and the diagnostic value of D-dimer in subjects with acute SARS-CoV-2 infection is not clear [8]. The increase in mortality associated with elevated D-dimer values in these patients may reflect an increased rate of APE, but it also could be a manifestation of disseminated intravascular coagulation or simply a higher level of systemic inflammation [7,9]. In addition, most of the published studies evaluating thrombotic complications of COVID-19 included intensive care unit (ICU) critical ill patients [10-14], and less is known on non- critical subjects.

The present study aimed to assess the prevalence of APE in patients hospitalized for non-critical COVID-19 who presented respiratory deterioration after admission, as well as to investigate the association of D-dimer and other clinical and biochemical variables with a confirmed diagnosis of APE in these subjects.

METHODS

The study was conducted at the Vimercate Hospital, a 500 bed General Hospital located in Lombardy, northern Italy. From February to May 2020, 712 patients with a confirmed diagnosis of COVID-19 were hospitalized in our institution. Among them, in April 2020 218 subjects were admitted to the internal medicine department wards after been evaluated in the Emergency Department.

In the first months of 2020, different reports suggesting an increasing risk of APE in COVID-19 patients were published [6]. Thus, in late march, a multidisciplinary group from our hospital issued an internal protocol with some recommendations to prevent and treat thrombotic complications in COVID-19 patients. The protocol strongly recommended performing a diagnostic CTPA to confirm or rule out APE in COVID-19 patients admitted to the internal medicine department wards presenting respiratory deterioration after admission, defined by a PaO₂/FiO₂ ratio reduction of > 30%.

Therefore, in the present retrospective cohort study we included all COVID-19 patients admitted to the internal medicine department (sub intensive and acute general beds of the internal medicine department wards) who had CTPA examinations performed from April 1st to April 31st for respiratory deterioration after admission, defined by a reduction of $\geq 30\%$ of the PaO₂/FiO₂ ratio. The exclusion criteria were: subjects with a story of bleeding diathesis and/or current use of anticoagulant therapy before hospitalization; age < 18, and critical COVID19 infection, defined by any of the following criteria a. respiratory failure needing mechanical assistance, b. shock c. "extra pulmonary" organ failure needing intensive care unit.

Electronic charts of all included patients were retrieved for evaluation. Trained study personnel retrospectively recorded relevant clinical, laboratory and treatment data. The diagnosis of COVID-19 was confirmed by RNA detection of the SARS-CoV-2.

Data of the following laboratory test performed 24-48 hours before performing CPTA were collected: D-dimer, international normalized ratio (INR), c-reactive protein (CRP), white blood cell count (WBCC), lactate dehydrogenase (LDH), alanine transaminase (ALT), aspartate transaminase (ALT), Creatinine (Cr), arterial partial pressure of carbon dioxide (PaCO₂), arterial oxygen partial pressure (PaO₂), fraction of inspired oxygen (FiO₂). Albumin, Interleukin 6, and Antithrombin III were measured within 24 hours of performing CTPA. D-dimer was measured by using HemosIL D-Dimer HS, a latex-enhanced turbidimetric immunoassay from Instrumentation Laboratory, on the fully automated coagulometer ACL TOP analyzer [15]. The normal value declared by the producer is less than 243 ng/mL [15].

Based on a retrospective chart review of clinical symptoms and patient history factors Wells score simplified version was calculated for each patient, and it was referred to the day when CPTA was performed. One point was given for the presence of each of the following items: (1) Previous PE or DVT; (2) Heart rate ≥ 100 b.p.m.; (3) Surgery or immobilization within the past four weeks; (4) Haemoptysis; (5) Active cancer (6); Clinical signs of DVT ; (7) Alternative diagnosis less likely than PE. Patients with < 2 point were categorized as PE unlikely and those with ≥ 2 points PE likely [16]. Since CTPA was performed in subjects suspected by presenting APE in addition to COVID-19 as causing respiratory deterioration, the last item of Wells score (alternative diagnosis less likely than PE) was considered present (1 point) in all cases.

Pulmonary embolism was confirmed on the basis of the presence of a filling defect in one or more pulmonary arteries up to sub-segmental arteries in CTPA, as stated by certified radiologists belonging to the hospital team, at the

time of the acquisition of images. Helical CTPA scans were performed on a Brilliance Philips CT scanner (Philips, Cleveland, OH, USA) which included 64-detector row capability.

This study was conducted in accordance with the amended Declaration of Helsinki. The protocol was approved by to the Local institutional review board, i.e. the Comitato Etico della Provincia Monza e Brianza. Waiver of written informed consent was granted due to the retrospective, observational design.

Statistical methods

Clinical characteristics and laboratory data were summarized by number and percentage for categorical variables and by median and interquartile range for numerical variables, in the whole study group and according to APE confirmed and excluded. To compare the different characteristics among patients with APE confirmed and APE excluded, Fisher exact test was used for categorical variables and Wilcoxon rank sum test was used for numerical variables.

To evaluate the diagnostic accuracy of D-dimer to predict APE, a ROC curve was fitted and the Area Under the ROC Curve (AUC) with pertinent 95% confidence interval (CI95%) was estimated. Optimal cut-off was obtained as the D-dimer value which maximizes both the specificity and the sensitivity. The diagnostic performance of different D-dimer cut-offs (standard cut-off: > 243 ng/mL, age adjusted cut off: patients' age $\times 5$, ROC curve best discriminating value: 2454 ng/mL) and Wells score (standard cut off: >2) was evaluated by computing the corresponding values of sensitivity and specificity, positive predictive value, negative predictive value with pertinent CI95%. Furthermore, four generalized linear regression models with binomial error and link log were fitted: the response was APE and the explanatory variable was a dichotomous variable discriminating patients with D-dimer value over the different cut offs or Wells score over 2. Results were reported as Relative Risk (RR) with corresponding CI95% and p-values.

All analyses were performed using R software version 4.0.0, with packages OptimalCutpoints, pROC and epiR added.

RESULTS

From 1st to 30th April 2020, 41 patients admitted to internal medicine department wards underwent a CTPA because respiratory deterioration after admission, defined by a PaO₂/FiO₂ ratio reduction of $\geq 30\%$, and represent the study population. The median (IRQ) age of the cohort was 71.7 (63-76) years, 30 (73%) were females, the median days (IRQ) since onset of symptoms to hospitalization was 8 (4-12) and the median days (IRQ) since onset of symptoms to CTPA was 11 (7-17). By the end of May 2020 in-hospital mortality of the cohort was 4.88%, with 2 patients still hospitalized and 90% already discharged. Clinical characteristics, treatment and outcomes of the study population are shown in Table 1.

Most frequent symptoms were fever (98%), dyspnea (73%) and cough (63%), and more than 70% of subjects were hypertensive (29 cases). Most patients have been treated empirically with hydroxychloroquine (95%) and steroids (80%), more than 70% with full anticoagulant doses of heparin before performing CTPA, and 61% with continuous positive airway pressure.

Eight out of 41 patients (19.51%, CI95%: 8.82% - 34.87%) presented a confirmed APE after performing CTPA. Except for a trend to a higher prevalence of chest pain among subjects with APE, (37% vs. 9%, $p = 0.077$), no statistically significant differences in patients with and without APE were found, with regards symptoms, comorbidities, treatment, Wells score and outcomes, Table 1. Among patients with confirmed APE a higher median value of white blood cell count (12.4 vs 8.4 $\times 10^9/L$, $p = 0.007$), and a trend for a lower value of alanine aminotransferase were found. The results of laboratory test in patients with APE confirmed and excluded are shown in Table 2.

The median values of D-dimer in patients with APE confirmed and excluded were 3236 and 1056 $\mu g/mL$, $p = 0.316$. The discriminant ability of D-dimer upon admission to identify confirmed vs. non confirmed APE showed an Area Under ROC Curve (AUC) of 0.62 (CI95%: 0.38 - 0.85), Figure 1. The optimal cut-off obtained by the ROC curve was 2454 ng/mL , with values of sensitivity: 63% (CI95%: 24-91%), specificity: 73% (CI95%: 54-87%), Positive Predictive Value: 36% (CI95%: 13-65%), Negative Predictive Value: 89% (CI95%: 71-98%). The standard D-dimer cut-off (243 ng/mL) showed, for a confirmed diagnosis of APE, values of sensitivity (CI95%): 88% (47-99%), specificity: 12% (3-28%), Positive Predictive Value: 1% (8-36%), and Predictive Negative Value: 80% (28-99%). Figures for the age-adjusted D-dimer cut-off (patients' age $\times 5$) and Wells score ≥ 2 (likely) were 88% (47-99%), 18% (7-35%), 21% (9-38%), 86% (42-99%), and 13% (0.3-53%), 85% (68-95%), 17% (0.42-64%), and 80% (63-92%), respectively. The RRs of the optimal D-dimer cut-off (2454 ng/mL) for confirmed APE was 3.31, p -value=0.073, whereas the standard and age adjusted D-dimer cut-offs and Wells score presented RRs (CI95%) of 0.97 (0.23-16.22, $p = 0.977$); 1.44 (0.32-24.77, $p = 0.711$) and 0.83 (0.05-3.67, $p = 0.851$), respectively, Table 3.

DISCUSSION

Although emerging data suggest that acutely ill patients with COVID-19 have an increased risk for APE, the actual prevalence of APE in this clinical setting is not well known. Most information on the thrombotic complications of COVID-19 derives from studies including critical ill patients and data on non-critical acutely ill subjects are lacking. In the present study we found that among patients who presented respiratory deterioration after been admitted to the internal medicine department with a diagnosis of non-critical COVID-19, near 20% presented a confirmed APE. In these subjects the best discriminating cut-off value of D-dimer for predicting APE was approximately 10 fold the standard threshold (2454 ng/mL), showing a trend to be associated with confirmed APE, albeit not statistically significant (RR: 3.21; CI95%: 0.92-13.97; p = 0.073). The values of D-dimer, when the standard and the age adjusted cut-offs were applied, the simplified Wells score, and other laboratory test did not appear to be clinically useful to identify patients with confirmed APE. Moreover, more than 70% have been empirically treated with full anticoagulant doses of heparin before performing CTPA.

Some points are worth discussing.

Firstly, the prevalence of APE we found in this clinical setting was high. This finding is even more noticeable when considering that most patients were receiving heparin at anticoagulant doses. As mentioned, most data on prevalence of APE and thrombotic events in general, are from COVID-19 ICU critical patients [8,10-15]. COVID-19 patients admitted to the ICUs of 3 Dutch hospitals, Klok and colleagues found a cumulative incidence of the composite thromboembolic outcome of 31% (CI95%: 20-41%) with APE representing 81% of all these thrombotic complication (n = 25) [10]. The rate of thromboembolic complications, mainly APE, was higher (11.7%) in COVID-19 patients referred to ICU from a French hospital, than that observed in a historical control group of non-COVID-19 ARDS patients (2.1%) [14]. These figures are much higher than the rates of APE observed in non COVID-19 ICU patients with sepsis or shock receiving guideline-recommended thromboprophylaxis [17]. In one of the few studies which describing thromboembolic events in non ICU COVID-19 patients, 29 out of 91 subjects (31.9%) who underwent CTPA presented APE, after admission to the internal medicine department [18]. Moreover, in the meta-analysis by Malas et al [19], the overall APE rate was 13% (95% CI:11-16%): 7% (95% CI:5-9%) among 16 non-ICU studies, 19% (95% CI:14-25%) among 18 ICU studies and 22% (95% CI:16-28%) among postmortem studies. Our study focused on non-ICU patients presenting respiratory deterioration after hospitalization, and our results confirm the finding of a high incidence of APE in this clinical setting. Secondly, the tools currently used in non COVID-19 patients to estimate the pre-test probability of APE as part of the diagnostic workup (Wells score and standard or age adjusted D-dimer values) seem not to be useful for predicting APE in COVID-19 patients. These findings are not surprising given these test have been validated in non COVID-19 patients with low-intermediate risk of APE. This was also true for other laboratory test, such as arterial blood gas analysis, interleukin-6, antithrombin III, AST, ALT, LDH, and serum creatinine. Our results suggest that a very high D-dimer cut-off (approximately 10 fold the standard threshold) may be associated to a confirmed APE. These data are in keeping with the results of a study reporting that a D-dimer threshold of 2660 µg/L detected all subject with APE among hospitalized COVID-19 patients [20]. These cut-off values are much higher than those used to exclude pulmonary embolus in non-ICU patients [21]. Even though a diagnostic strategy for APE suspicion based on a single variable (D-dimer) presents evident limitations and guidelines recommend multivariable predicting algorithms for non-COVID-19 patients [21], the diagnostic value of a sharp increase of D-dimer as marker of increased risk of APE in COVID-19 patients remains to be established. Some authors have proposed using age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in COVID-19 patients [22]. Yet, in our study the age adjusted threshold did

not show to be clinically useful. Thirdly, in our study, among acutely ill patients presenting respiratory deterioration after admission to the internal medicine department wards with a diagnosis of COVID-19 during the so-called “first wave”, most have been treated with full anticoagulant doses of heparin before performing CTAP. The fact that these patients have been certainly considered at a very high risk of having APE probably lead physicians to prescribe full anticoagulation instead of prophylaxis with heparin, also because at the time of the study period (April 2020), no clear expert clinical guidance had been issued on this subject. Interestingly, also in the study by Klok et al [10] it was described as heparin regimes differed between hospitals and the doses increased over time, presumably reflecting an increasing concern on the risk of developing APE in COVID-19 patients. However, empirical use of anticoagulant doses of heparin may not only be ineffective but deleterious since it has been well established that high-dose LMWH administration may be associated with increased incidence of major and fatal bleeding [23]. In fact, pending the results of randomized clinical trials, in patients without a confirmed diagnosis of APE, most authors recommend thromboprophylaxis with LMWH for non-ICU COVID-19 patients [24].

Finally, in COVID-19 patients, given the high prevalence of APE, the unavailability of satisfactory tools for estimating pretest probability and the potential high risk of complications associated with the use of empirical anticoagulation, a high index of suspicion for performing CTPA should be strongly recommended, in order to exclude or to confirm APE. Main contraindications for CTPA are an impaired renal function and hemodynamic instability to undergo the test. Our results show that these conditions are relatively rare among non-ICU COVID-19 patients.

The main limitations of our study are retrospective and monocentric design and small sample size, with large CI95% limiting the precision of estimates and the generalizability of results. Yet, we included all consecutive subjects fulfilling the inclusion criteria, to reduce selection bias. Thus, our study population would represent a real world sample severe COVID-19 patients admitted to internal medicine department wards who presented respiratory deterioration. Nevertheless, to confirm our findings, larger and multicenter studies are needed. Moreover, our study population was limited to 41 subjects who presented respiratory deterioration after hospitalization thus performing CPAP, from a total of 218 non-ICU COVID19 patients admitted to the internal medicine department wards of our hospital in the study period (April 2020). No data may be provided on the rates of AP in patients who did not presented respiratory deterioration, because CPAP was not performed in these subjects.

Conclusions

Among patients hospitalized in the internal medicine department with a diagnosis of non-critical COVID-19, in whom a CTPA was performed because of respiratory deterioration after admission, the prevalence of confirmed APE is high (20%).

Some validated tools used in the APE diagnostic workup of non COVID-19 patients, such as D-dimer (standard and age-adjusted cutoffs) and Wells score, along with other commonly used laboratory test, do not seem to be clinically useful to identify patients with confirmed APE.

Most subjects have been treated empirically with full anticoagulant doses of heparin before performing CTPA, even though in many cases CTPA did not confirmed the diagnosis of APE.

While awaiting additional evidence and the development of new diagnostic and therapeutic algorithms, our results support the use of a high index of suspicion for performing CTPA to exclude or to confirm APE, as the most appropriate diagnostic approach in this clinical setting.

REFERENCES

1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020 Feb 24. doi: 10.1001/jama.2020.2648 [Epub ahead of print]
2. Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. *JAMA*. 2020;10.1001/jama.2020.4031. doi:10.1001/jama.2020.4031 [Epub ahead of print]
3. Kho J, Ioannou A, Van den Abbeele K, Mandal AKJ, Missouriis CG. Pulmonary embolism in COVID-19: Clinical characteristics and cardiac implications. *Am J Emerg Med*. 2020;38(10):2142-2146. doi: 10.1016/j.ajem.2020.07.054. Epub 2020 Jul 24. PMID: 33046316; PMCID: PMC7378013.
4. China CDC Weekly. Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. <http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51>. Accessed August 1 2020.
5. Ehrman RR, Collins J, Harrison N. Prevalence of Pulmonary Embolism in Emergency Department Patients With Suspected COVID-19: The Truth Remains Unknown. *Acad Emerg Med*. 2020;27(11):1216-1217. doi: 10.1111/acem.14137. Epub 2020 Oct 16. PMID: 32969120; PMCID: PMC7537082.
6. Li T, Cheng GS, Pipavath SNJ, Kicska GA, Liu L, Kinahan PE, Wu W. The novel coronavirus disease (COVID-19) complicated by pulmonary embolism and acute respiratory distress syndrome. *J Med Virol*. 2020;92(10):2205-2208. doi: 10.1002/jmv.26068. Epub 2020 Jun 12. PMID: 32470156; PMCID: PMC7283730.
7. Franco-Moreno A, Herrera-Morueco M, Mestre-Gómez B, Muñoz-Rivas N, Abad-Motos A, Salazar-Chiriboga D, Duffort-Falcó M, Medrano-Izquierdo P, Bustamante-Fermosel A, Pardo-Guimera V, Ulla-Anés M, Torres-Macho J; Infanta Leonor Thrombosis Research Group. Incidence of Deep Venous Thrombosis in Patients With COVID-19 and Pulmonary Embolism: Compression Ultrasound COVID Study. *J Ultrasound Med*. 2020 Oct 5;10.1002/jum.15524. doi: 10.1002/jum.15524. Epub ahead of print.
8. Gungor B, Atici A, Baycan OF, Alici G, Ozturk F, Tugrul S, Asoglu R, Cevik E, Sahin I, Barman HA. Elevated D-dimer levels on admission are associated with severity and increased risk of mortality in COVID-19: A systematic review and meta-analysis. *Am J Emerg Med*. 2021 Jan;39:173-179. doi: 10.1016/j.ajem.2020.09.018. Epub 2020 Sep 14. PMID: 33069541; PMCID: PMC7489326.
9. Ibañez C, Perdomo J, Calvo A, Ferrando C, Reverter JC, Tassies D, Blasi A. High D dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there? *J Thromb Thrombolysis*. 2020 Jul 15:1–5. doi: 10.1007/s11239-020-02226-0. Epub ahead of print.
10. Klok FA, Kruijff MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. 2020;pii: S0049-3848(20)30120-1. doi: 10.1016/j.thromres.2020.04.013. [Epub ahead of print]
11. Rieder M, Goller I, Jeserich M, Baldus N, Pollmeier L, Wirth L, Supady A, Bode C, Busch HJ, Schmid B, Duerschmied D, Gauchel N, Lother A. Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19. *J Thromb Thrombolysis*. 2020;50(3):558-566. doi: 10.1007/s11239-020-02202-8.
12. Thomas W, Varley J, Johnston A, et al. Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom. *Thromb Res*. 2020;191:76-77. doi: 10.1016/j.thromres.2020.04.028. [Epub ahead of print]
13. Litjens JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. *J Thromb Haemost*. 2020. doi: 10.1111/jth.14869. [Epub ahead of print].
14. Helms J, Tacquard C, Severac F, et al. CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. *Intensive Care Med*. 2020. doi: 10.1007/s00134-020-06062-x. [Epub ahead of print]
15. Salvagno GL, Lippi G, Montagnana M, et al. Performance of the automated and rapid HemosIL D-Dimer HS on the ACL TOP analyzer. *Blood Coagul Fibrinolysis*. 2008;19(8):817-821. doi:10.1097/MBC.0b013e32830f1bae
16. Gibson NS, Sohne M, Kruijff MJ, et al. Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. *Thromb Haemost* 2008;99(1):229–234.

17. Kaplan D, Casper TC, Elliott CG, et al. VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock. *Chest*. 2015;148(5):1224-1230. doi: 10.1378/chest.15-0287.
18. Mestre-Gómez B, Lorente-Ramos RM, Rogado J, Franco-Moreno A, Obispo B, Salazar-Chiriboga D, Saez-Vaquero T, Torres-Macho J, Abad-Motos A, Cortina-Camarero C, Such-Díaz A, Ruiz-Velasco E, Churruga-Sarasqueta J, Muñoz-Rivas N; Infanta Leonor Thrombosis Research Group. Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis. *J Thromb Thrombolysis*. 2020 Jun 29:1–7. doi: 10.1007/s11239-020-02190-9. Epub ahead of print.
19. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. *EclinicalMedicine*. 2020 Dec;29:100639. doi: 10.1016/j.eclinm.2020.100639. Epub 2020 Nov 20. PMID: 33251499; PMCID: PMC7679115.
20. Leonard-Lorant I, Delabranche X, Severac F, et al. Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels. *Radiology*. 2020;201561. doi: 10.1148/radiol.2020201561. [Epub ahead of print]
21. Vedovati MC, Giustozzi M, Franco L. Beyond the guidelines: Novelties, changes and unsolved issues from the 2019 ESC guidelines on pulmonary embolism. *Eur J Intern Med*. 2020;72:1-4. doi:10.1016/j.ejim.2019.11.001
22. Roncon L, Zuin M, Zonzin P. Age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in COVID-19 patients. *Thromb Res*. 2020;190:102. doi: 10.1016/j.thromres.2020.04.021. [Epub ahead of print]
23. Conti CB, Henchi S, Coppeta GP, Testa S, Grassia R. Bleeding in COVID-19 severe pneumonia: The other side of abnormal coagulation pattern?. *Eur J Intern Med*. 2020;77:147-149. doi:10.1016/j.ejim.2020.05.002
24. Cattaneo M, Bertinato EM, Biocchi S, et al. Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?. *Thromb Haemost*. 2020;10.1055/s-0040-1712097. doi:10.1055/s-0040-1712097

LEGENDS TO TABLES AND FIGURES:

Table 1. Clinical characteristics of the study population, treatment during hospitalization and outcomes.

APE: acute pulmonary embolism. CTPA: computed tomography pulmonary angiography. CCI: Charlson Comorbidities Index. CPAP continuous positive airway pressure.

Table 2. Laboratory data in patients with APE confirmed and excluded.

APE: acute pulmonary embolism; INR=international normalized ratio CRP=c-reacted protein; WBC=white blood cell count; LDH= lactate dehydrogenase ALT=alanine aminotransferase; AST=aspartate transaminase; Cr=Creatinine; PaCO₂=arterial partial pressure of carbon dioxide; PaO₂=arterial oxygen partial pressure;SO₂=oxygen saturation; PaO₂: arterial oxygen partial pressure; FiO₂: fraction of inspired oxygen


Table 3. Diagnostic performance of different D-dimer cut-offs and Wells score for the diagnosis of APE.

APE: acute pulmonary embolism. RR: relative risk.

Figure 1. ROC curve to estimate the optimal cut-off value of D-dimer for predicting APE.

APE: acute pulmonary embolism.

Figure 1. ROC curve to estimate the optimal cut-off value of D-dimer for predicting APE.



APE: acute pulmonary embolism.

TABLE 1. Clinical characteristics of the study population, treatment during hospitalization and outcomes.

Characteristics	Total (n=41)	APE confirmed (n=8)	APE excluded (n=33)	p value (APE confirmed vs excluded)
Age, median (IQR)	71.7 (63 - 76.2)	67 (57.3 - 74.4)	72.1 (63.1 - 76.2)	0.459
Female, n (%)	30 (73.17%)	6 (75%)	24 (72.73%)	1.000
Time since onset of symptoms to hospitalization, median days (IQR)	8 (4 - 12)	8.5 (3.5 - 14.8)	8 (4 - 12)	0.830

Time since hospitalization to CTPA, median days (IQR)	11 (7 - 17)	11 (1.2 - 13.5)	11 (8 - 17)	0.680
Symptoms				
Fever, n (%)	40 (97.56%)	8 (100%)	32 (96.97%)	1.000
Cough, n (%)	26 (63.41%)	5 (62.5%)	21 (63.64%)	1.000
Dyspnea, n (%)	30 (73.17%)	4 (50%)	26 (78.79%)	0.178
Chest pain, n (%)	6 (14.63%)	3 (37.5%)	3 (9.09%)	0.077
Diarrhea, n (%)	13 (31.71%)	2 (25%)	11 (33.33%)	1.000
Comorbidities				
Hypertension, n (%)	29 (70.73%)	4 (50%)	25 (75.76%)	0.202
Diabetes, n (%)	11 (26.83%)	2 (25%)	9 (27.27%)	1.000
Chronic heart diseases, n (%)	9 (21.95%)	1 (12.5%)	8 (24.24%)	0.659
Active Cancer, n (%)	3 (7.32%)	0 (0%)	3 (9.09%)	1.000
Smoking, n (%)	0 (0%)	0 (0%)	0 (0%)	1.000
CCI, median (IQR)	1 (0 - 1)	0 (0 - 1)	1 (0 - 2)	0.173
Treatment				
Heparin at prophylactic dose before performing CTPA, n (%)	4 (9.76%)	0 (0%)	4 (12.12%)	0.569
Heparin at anticoagulant dose before performing CTPA, n (%)	29 (70.73%)	5 (62.5%)	24 (72.73%)	0.672
Hydroxychloroquine, n (%)	39 (95.12%)	8 (100%)	31 (93.94%)	1.000
Any antiviral therapy, n (%)	12 (29.27%)	3 (37.5%)	9 (27.27%)	0.672
Steroids, n (%)	33 (80.49%)	7 (87.5%)	26 (78.79%)	1.000
CPAP, n (%)	25 (60.98%)	5 (62.5%)	20 (60.61%)	1.000
Wells score within 48 hours before CTPA, median (IQR)	2 (2 - 2)	2 (1.8 - 2)	2 (2 - 2)	0.681
Outcome				
Discharged, n (%)	37 (90.24%)	7 (87.5%)	30 (90.91%)	1.000
Still hospitalized, n (%)	2 (4.88%)	1 (12.5%)	1 (3.03%)	1.000
In-hospital mortality, n (%)	2 (4.88%)	0 (0%)	2 (6.06%)	1.000

APE: acute pulmonary embolism; IQR: interquartile range;CTPA: computed tomography pulmonary angiography. CCI: Charlson Comorbidities Index. CPAP: continuous positive airway pressure.

TABLE 2. Laboratory data in patients with APE confirmed and excluded.

	Normal Range Missing Data (n)	All patients (n=41)	APE confirmed (n=8)	APE excluded (n=33)	p value (APE confirmed vs excluded)
D-dimer (ug/mL), median (IQR)	0 - 243 ug/mL (0)	1488 (446 - 4211)	3236 (1943 - 4735)	1056 (446 - 2634)	0.316
INR, median (IQR)	0.8 - 1.2 (9)	1.2 (1.1 - 1.3)	1.2 (1.1 - 1.2)	1.2 (1.1 - 1.3)	0.749
Albumin (g/dL), median (IQR)	3.7 - 5.3 g/dL (10)	3.0 (2.9 - 3.3)	2.7 (2.4 - 3.1)	3.1 (3 - 3.3)	0.284
CRP (mg/dL), median (IQR)	0.0 - 8.0 mg/dL (0)	51 (18 - 140)	67 (40.2 - 157.8)	50 (16 - 135)	0.439
WBCC (*10 ⁹ /L) , median (IQR)	4.0 - 11.0 *10 ⁹ /L (0)	9.1 (7 - 12.2)	12.4 (10.4 - 13.4)	8.4 (6.4 - 10.5)	0.007
LDH (U/L), median (IQR)	135 - 225 U/L (1)	332 (251.8 - 419.2)	330 (249.2 - 340.8)	354.5 (251.8 - 441.8)	0.437
ALT (U/L), median (IQR)	5 - 43 U/L (1)	41 (27.8 - 53.2)	34.5 (23 - 39)	44.5 (28.8 - 55)	0.058
AST (U/L), median (IQR)	3 - 45 U/L (0)	43.5 (30.8 - 70)	44 (28 - 58.2)	43.5 (30.8 - 73.2)	0.488
Cr (μmol/L), median (IQR)	0.6 - 1.2 μmol/ (0)	0.9 (0.8 - 1)	0.9 (0.8 - 1.1)	0.8 (0.8 - 1)	0.383
Interleukin 6 (pg/mL), median (IQR)	< 7 pg/mL (15)	11.9 (7.8 - 38.7)	20.8 (10.6 - 37.8)	11.6 (7 - 35.9)	0.287
Antithrombin III, median (IQR)	80 - 120 (19)	100.5 (90.2 - 114.2)	89 (88 - 103)	102 (95 - 115)	0.456

PaCO ₂ (mmHg), median (IQR)	32 – 45 mmHg (0)	37 (34 - 42)	42 (38 - 43.2)	36 (34 - 39)	0.171
PaO ₂ (mmHg, median (IQR))	83 – 108 mmHg (0)	95 (71 - 143)	129 (65.2 - 146.2)	91 (71 - 139)	0.934
PaO ₂ /FiO ₂ ratio, median (IQR)	> 350 (0)	123 (93 - 186)	161 (127.8 - 195.8)	117 (93 - 174)	0.633

APE: acute pulmonary embolism; IQR: interquartile range; INR: international normalized ratio; CRP:c-reacted protein; WBC:white blood cell count; LDH: lactate dehydrogenase; ALT: alanine aminotransferase; AST:aspartate transaminase; Cr: Creatinine; PaCO₂: arterial partial pressure of carbon dioxide; PaO₂:arterial oxygen partial pressure; FiO₂: fraction of inspired oxygen.

Table 3. Diagnostic performance of different D-dimer cut-offs and Wells score for the diagnosis of APE.

	N of cases (%) with values higher than the cut-off	RR (CI95%) for the confirmed diagnosis of APE	P value
D-dimer (standard cut-off:243 ng/mL)	36 (87.8%)	0.97 (0.23 - 16.22)	0.977
D-dimer (Age adjusted: patients' age x 5)	34 (82.93%)	1.44 (0.32 - 24.77)	0.711
D-dimer (cut-off: ROC CURVE best discriminating value: 2454 ng/mL)	14 (34.15%)	3.21 (0.92 - 13.97)	0.073
Wells score (≥ 2 : likely)	6 (14.63%)	0.83 (0.05 - 3.67)	0.851

APE: acute pulmonary embolism; RR: relative risk;CI95%: 95% confidence interval.